 |
 |
Synta has a pipeline of five diverse, novel small molecule programs in two major
therapeutic areas: cancer and autoimmune/inflammatory disease. All our
compounds were internally discovered and developed and are currently 100% owned
by Synta.
We seek to expand the potential of our pipeline by selectively partnering
program rights, by geography or by indication, where we believe partnerships
can enhance the total value of the program.
Our most clinically advanced program is ganetespib, a potent,
synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90) that is
currently being studied in multiple clinical trials including a Phase 2b/3
registration-enabling trial in combination with docetaxel in non-small cell
lung cancer.
Synta is also developing small-molecule drugs targeting a novel family of ion
channels that are critical to immune cell function, known as calcium
release-activated calcium modulator (CRACM) channels. The goal
is to develop a novel category of oral, disease-modifying agents for the
treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary
disease (COPD), allergy, transplant rejection, and other autoimmune diseases
and inflammatory conditions.
Other Synta programs include:
-
Elesclomol, a first-in-class, investigational drug candidate
that triggers programmed cell death (apoptosis), in cancer cells through a
novel mechanism: disrupting cancer cell energy metabolism by selectively
targeting the electron transport chain in cancer cell mitochondria. Elesclomol
is currently being studied in a Phase 1 trial in acute myeloid leukemia as well
as a Phase 2 trial in combination with paclitaxel in ovarian cancer that is
being conducted by the Gynecologic Oncology Group (GOG).
-
STA-9584, a Vascular Disrupting Agent (VDA) currently being
developed through a $1 million grant under the Department of Defense Prostate
Cancer Research Program (PCRP) of the Office of the Congressionally Directed
Medical Research Programs (CDMRP. This funding supports the study of STA-9584
in advanced prostate cancer.
-
Our small molecule drug candidates that inhibit the production of the cytokines
interleukin-12 (IL-12), and interleukin-23 (IL-23), which are
believed to be important regulators of the biological processes underlying
certain autoimmune and inflammatory diseases. The IL-12 cytokine family
(including IL-12 and IL-23) is the master regulator of the TH1 pathway which
drives major chronic inflammatory diseases, including Crohn's disease,
psoriasis, rheumatoid arthritis, and multiple sclerosis.
We have an extensive intellectual property portfolio consisting of over 700
issued or pending patents. All Synta compounds currently in clinical trials
represent novel chemical structures protected by issued or allowed composition
of matter patents, as well as a robust package of related structure, mechanism,
formulation, manufacturing, and administration patents.
For further information on partnering or licensing opportunities, please
contact:
Christian Cortis, Ph.D.
Head of Business Development
Synta Pharmaceuticals Corp.
45 Hartwell Avenue
Lexington MA, 02421
ccortis AT syntapharma.com
tel: 781-541-7234
[Top of page]
|
|
